Stanley A. Okoro, MD, FACS

• Division of Plastic and Reconstructive Surgery
• University of Texas Health Science Center at San Antonio
• San Antonio, Texas

What are some potential causes of the breakthrough bleeding that the patient has been experiencing What strategy would you recommend to eliminate or minimize the potential adverse effects experienced by the patient Although the extended duration of activity of this product may offer women the advantage of less frequent administration muscle relaxant name brands purchase urispas cheap, it is important to note that on discontinuation of Depo-Provera muscle relaxant 4211 generic urispas 200 mg on-line, the return of fertility can be delayed by approximately 10 to 12 months (range 4­31 months) spasms gelsemium semper purchase on line urispas. This product differs from Depo-Provera in that it is given subcutaneously rather than intramuscularly spasms sphincter of oddi urispas 200 mg purchase amex, and it contains only 104 mg of medroxyprogesterone acetate (~30% less hormone) administered every 3 months for the prevention of pregnancy spasms 1983 movie buy 200 mg urispas with amex. Clinical trials have demonstrated that the subcutaneous formulation of depot medroxyprogesterone acetate is as effective as the intramuscular formulation in the prevention of pregnancy. The original theory is that the presence of a foreign body in the uterus causes an inflammatory response that interferes with implantation. Progestincontaining implantable contraceptives can have direct effects on the uterus, such as thickening of cervical mucus and alterations to the endometrial lining. Ingredient Levonorgestrel Levonorgestrel Copper Etonorgestrel Etonorgestrel Dosage Form Intrauterine device Intrauterine device Intrauterine device Implantable device Implantable device Duration Up to 5 years Up to 3 years Up to 10 years Up to 3 years Up to 3 years It is important to evaluate a patient to determine whether she is an appropriate candidate for an implantable contraceptive. The most common adverse effects are abdominal/pelvic cramping, abnormal uterine bleeding, and expulsion of the device. Nonpharmacologic Contraceptive Methods »» Barrier Contraceptives As an alternative to hormonal contraceptives, several barrier contraceptive options are available for the prevention of pregnancy. Although barrier contraceptives are associated with far fewer adverse effects compared with hormonal contraceptives, their efficacy is highly user-dependent. Diaphragms and Cervical Caps Diaphragms and cervical caps are dome-shaped rubber caps that are placed over the cervix to provide barrier protection during intercourse. Both diaphragms and cervical caps require fitting by a health care professional, and they must be refitted in the event of weight gain or weight loss. Diaphragms or cervical caps typically can be placed over the cervix as much as 6 hours prior to intercourse. They must be left in place for at least 6 hours after intercourse before they can be removed. Diaphragms and cervical caps are used along with spermicides to prevent pregnancy. When sexual intercourse is repeated with the diaphragm, reapplication of the spermicide is necessary. However, when sexual intercourse is repeated with a cervical cap, reapplication of the spermicide typically is not necessary. Spermicides may be used alone, with a barrier method, or adjunctively with other forms of contraceptives to provide additional protection against unwanted pregnancy. Condoms Condoms, which are available for both male and female use, act as physical barriers to prevent sperm from coming into contact with ova. When used correctly, condoms can be very effective in prevention of unwanted pregnancy. When stored improperly or when used with oil-based lubricants, however, latex condoms can break during intercourse, increasing the risk of pregnancy. In some cases, rather than practicing abstinence during the fertile period, some couples may prefer to employ barrier methods or spermicides as a means of preventing pregnancy rather than to avoid intercourse altogether. The calendar (rhythm) method involves counting the days in the menstrual cycle and then using a mathematical equation to determine the fertile window. The symptothermal method, which is considered to be the most difficult to learn but potentially the most effective, is a combination of both the temperature method and the cervical mucus method. Three days have elapsed since she took her last active pill, and she reports having had unprotected sexual intercourse last night. The patient is very concerned about her risk of pregnancy and is interested to learn more about emergency contraception and what her options are. The available products are listed in the Table 48­7 along with information on availability and correct dosage. Common side effects include headache, nausea, abdominal pain, dysmenorrhea, fatigue, and dizziness. If severe abdominal pain occurs, patients should be referred to their health care provider for evaluation of risk of an ectopic pregnancy. Fertility Awareness­Based Methods Fertility awareness­based methods (natural methods) represent another nonpharmacologic means of pregnancy prevention. Although failure rates of such methods can be high, some couples Table 48­7 Emergency Contraception Product Plan B One-Step Next Choice One Dose My Way Levonorgestrel ella Where stocked Over the counter Behind the counter Behind the counter Behind the counter Behind the counter Availability All ages with no identification required Over the counter for 17 years and older; prescription required for 16 years and younger Over the counter for 17 years and older; prescription required for 16 years and younger Over the counter for 17 years and older; prescription required for 16 years and younger Only as a prescription Ingredient Levonorgestrel Levonorgestrel Levonorgestrel Levonorgestrel Ulipristal acetate Dose 1. Therapy Evaluation: · At follow-up visits, assess blood pressure, weight, and menstrual patterns for changes from baseline. Follow-up Evaluation: · Instruct the patient to consult a health care professional upon noticing or experiencing any warning signs. Thus schedule a follow-up visit 3 to 6 months after initiating a new contraceptive. Yearly checkups usually are sufficient for patients who are doing well on a particular product. Strict adherence to the prescribed hormonal contraceptive regimen is essential for effective prevention of unintended pregnancy. When a contraceptive dose is missed, the risk of accidental pregnancy may be increased. Depending on how many doses were missed, the contraceptive formulation being used, and the phase of the cycle during which doses were missed, counseling regarding the use of additional methods of contraception may be warranted. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 19902008. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Progestin and estrogen: Potency of combination oral contraceptives and endometrial cancer risk. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30 year population-based study. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: A meta-analysis and formal sensitivity analysis. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. Describe the underlying etiology and pathophysiology of dysmenorrhea, amenorrhea, anovulatory bleeding, and menorrhagia and how they relate to selecting effective treatment modalities. Describe the clinical presentation of dysmenorrhea, amenorrhea, anovulatory bleeding, and menorrhagia. Recommend appropriate nonpharmacologic and pharmacologic interventions for patients with dysmenorrhea, amenorrhea, anovulatory bleeding, and menorrhagia. Identify the desired therapeutic outcomes for patients with dysmenorrhea, amenorrhea, anovulatory bleeding, and menorrhagia. Design a monitoring plan to assess the effectiveness and adverse effects of pharmacotherapy for dysmenorrhea, amenorrhea, anovulatory bleeding, and menorrhagia. These disorders negatively affect quality of life, reproductive health, work productivity, and may lead to adverse long-term health consequences, such as osteoporosis or polycystic ovarian syndrome. Primary dysmenorrhea is pain in the setting of normal pelvic anatomy and physiology, whereas secondary dysmenorrhea is associated with underlying pelvic pathology. This induces uterine contractions, stimulating pain fibers, reducing uterine blood flow, and causing uterine hypoxia. By inhibiting prostaglandin production, they exert analgesic properties, decrease uterine contractions, and reduce menstrual blood flow. Choice of one agent over another is based on cost, convenience, and patient preference. Her last menstrual cycle was 9 days ago, and she had her first menstrual cycle at age 11. She is sexually active with one partner and has had 5 sexual partners in the past. She has been using acetaminophen or ibuprofen as needed for pain and is a current smoker. Symptoms · Crampy pelvic pain (lasting 1­3 days) beginning shortly before or at menses onset. Associated symptoms may include nausea, vomiting, diarrhea, hypertension, and/or tachycardia. Laboratory Tests · Sexually active females should receive a pelvic examination to screen for sexually transmitted diseases. Other Diagnostic Tests · Pelvic ultrasound may be used to identify anatomic abnormalities (eg, masses/lesions), ovarian cysts, or endometriomas. Primary amenorrhea occurs prior to age 15 in the presence of normal secondary sexual development or within 5 years of thelarche (if occurring before age 10). Depot medroxyprogesterone 150 mg intramuscularly every 12 weeks As noted above acetatea Letrozole 2. Epidemiology and Etiology Unrecognized pregnancy is the most common cause of amenorrhea, therefore, a urine pregnancy test should be one of the first steps in evaluating amenorrhea. Amenorrhea not related to pregnancy, lactation, or menopause occurs in 3% to 4% of women. What nonpharmacologic and pharmacologic therapies are recommended for this patient What monitoring parameters are necessary to employ in assessing efficacy and safety of the therapeutic options Amenorrhea attributable to hypoestrogenism (eg, premature ovarian insufficiency) can cause hot flashes and dyspareunia. In prepubertal females, the absence of secondary sexual characteristics and menarche may occur. To minimize risk of endometrial hyperplasia and cancer, progestin should also be given to women with an intact uterus. Dopamine Agonists In women with hyperprolactinemia who desire conception, dopamine agonists are an option. Withdrawal bleeding occurs with intramuscularly injected progesterone and oral medroxyprogesterone acetate in 70% and 95% of patients, respectively. All patients experiencing amenorrhea should follow a diet rich in calcium and vitamin D to support bone health. Supplemental calcium and vitamin D (1200 mg/800 International Units per day) should be recommended for patients with inadequate dietary consumption. Amenorrhea secondary to undernutrition or anorexia may respond to weight gain and psychotherapy. The cause of amenorrhea and appropriate treatment must be identified promptly in this population because hypoestrogenism contributes negatively to bone development. During the cycle, the endometrium proliferates and undergoes secretory changes and desquamation. This is influenced by estrogen alone, then by estrogen and progesterone, and culminates with estrogen and progesterone withdrawal. In anovulatory women, a corpus luteum is not formed, and the ovary does not secrete progesterone. The endometrium becomes vascular and fragile, resulting in noncyclic menstrual bleeding. All women of reproductive age should have a pregnancy test when presenting with irregular menstrual bleeding. As ovarian function declines, estrogen secretion continues, and progesterone secretion decreases. In overweight or obese women, a 5% reduction in weight has been associated with resumption of menses, improved pregnancy rates, and decreased hirsutism, glucose, and lipid levels. For short term, it appears that ablation or resection results in less morbidity and shorter recovery periods. Estrogen Estrogen is the recommended treatment for managing acute bleeding episodes. All previous Pap smears have been normal, and there is no history of sexually transmitted infections. She had one successful pregnancy that took "several years" and three courses of clomiphene due to "follicles" on her ovaries. Anovulatory Bleeding in Adolescents Anovulatory cycles are common in the perimenarchal years. Thus, the patient should be evaluated for blood dyscrasias, including von Willebrand disease, prothrombin deficiency, and idiopathic thrombocytopenia purpura. Many women with less than 80 mL of blood loss seek medical attention with concerns of containment flow problems, unpredictable heavy flow, reduced quality of life, and other dysmenorrhea symptoms.

Signs and symptoms of hypophosphatemia include paresthesias spasms during meditation urispas 200 mg for sale, muscle weakness muscle relaxant without aspirin urispas 200 mg purchase with mastercard, myalgias 2410 muscle relaxant 200 mg urispas mastercard, bone pain muscle relaxant leg cramps urispas 200 mg buy online, anorexia spasms in rectum cheap urispas 200 mg, nausea, vomiting, red blood cell breakdown (hemolysis), acute respiratory failure, seizures, and coma. Diarrhea may be a doselimiting side effect with oral phosphate replacement products. Injectable phosphate products are reserved for patients with severe hypophosphatemia or those in the intensive care unit. Dietary restriction of phosphate and protein is effective for most minor elevations. Phosphate binders such as aluminum-based antacids, calcium carbonate, calcium acetate (PhosLo, available as generic), sevelamer hydrochloride (Renagel, Genzyme), sevelamer carbonate (Renvela, Genzyme, Global), and lanthanum carbonate (Fosrenol, Shire) may be necessary for some patients (typically those with chronic renal failure). Magnesium catalyzes and/or activates more than 300 enzymes, provides neuromuscular stability, and is involved in myocardial contraction. Magnesium is generally not part of standard chemistry panels and therefore must be ordered separately. Clinicians should evaluate the magnesium concentration in these patients and correct if low. In order for calcium and potassium concentrations to normalize, magnesium supplementation is often required. Medications that potentially can cause hypomagnesemia include aminoglycoside antibiotics, amphotericin B (available as generic), cisplatin (available as generic), insulin, cyclosporine (available as generic), loop diuretics, and thiazide diuretics. Magnesium oxide (Mag-Ox, Blaine Pharmaceuticals and various manufacturers) 400-mg tablets contain 241 mg (20 mEq or 10 mmol) of magnesium, and magnesium chloride hexahydrate tablets (Slow-Mag, Purdue) contains 64 mg of elemental magnesium. Ten milliliters of a 10% magnesium sulfate solution contains 1 g of magnesium, which is equivalent to 98 mg (8. Administration of magnesium sulfate injection to pregnant women longer than 5 to 7 days may lead to low calcium levels and bone fractures in the developing baby or fetus. Because magnesium concentration does not correlate well with total body magnesium stores, magnesium is often administered empirically to critically ill patients. Mild hypermagnesemia is present if the serum magnesium concentration is between 2. Severe hypermagnesemia is present if the serum magnesium concentration is greater than 13 mEq/L (6. Using the equation (1500 mL + 20 mL for each kilogram greater than 20 kg), calculate the rate of fluid administration for the total fluids needed in this 24-hour period and over the next 48 hours. Common fluid­ electrolyte and acid­base problems in the intensive care unit: Selected issues. The Albumin Reviewers (Alderson P, Bunn F, Lefebvre C, Li Wan Po A, Li L, Roberts I, Schlerhout G. Perel P, Roberts I, Ker K Colloids versus crystalloids for fluid resuscitation in critically ill patients. Similarly, disturbances in serum sodium, potassium, calcium, phosphorus, and magnesium are ubiquitous and must be mastered by all clinicians. Dysregulation of fluid and/or electrolyte status has serious implications regarding the concepts of drug absorption, volumes of distribution, and toxicity. Similarly, many medications can disrupt fluid and/or electrolyte balance as an unintended consequence. A new graduated regimen for phosphorous replacement in patients receiving nutritional support. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: A review. Efficacy and safety of potassium infusion therapy in hypokalemic critically ill patients. Compare and contrast the four primary acid­base disturbances within the human body. Apply simple formulas in a systematic manner to determine the etiology of simple acid­base disturbances and the adequacy of compensation. Integrate the supplemental concepts of the anion gap and the excess gap to further assess for complex acid­base disturbances. Propose an appropriate treatment plan for patients with deranged acid­base physiology. G iven its reputation for complexity and the need to memorize innumerable formulas, acid­base analysis intimidates many health care providers. In reality, acid­base disorders always obey well-defined biochemical and physiological principles. Rigorous use of a systematic approach to arterial blood gases increases the likelihood that derangements in acid­base physiology are recognized and correctly interpreted. This chapter outlines a clinically useful approach to acid­base abnormalities and then applies this approach in a series of increasingly complex clinical scenarios. Disturbances of acid­base equilibrium occur in a wide variety of illnesses and are among the most frequently encountered disorders in critical care medicine. The importance of a thorough command of this content cannot be overstated given that acid­ base disorders are remarkably common and may result in significant morbidity and mortality. Although severe derangements may affect virtually any organ system, the most serious clinical effects are cardiovascular (arrhythmias, impaired contractility), neurologic (coma, seizures), pulmonary (dyspnea, impaired oxygen delivery, respiratory fatigue, respiratory failure), and/ or renal (hypokalemia). Changes in acid­base status also affect multiple aspects of pharmacokinetics (clearance, protein binding) and pharmacodynamics. Acid­base status is traditionally represented in terms of pH, the negative logarithm of [H+]. Because the kidneys excrete less than 1% of the estimated 13,000 mEq (13,000 mmol) of H+ ions generated in an average day, renal failure can be present for prolonged periods before lifethreatening imbalances occur. Conversely, cessation of breathing for minutes results in profound acid­base disturbances. If a patient has an isolated primary acid­base disorder that is not accompanied by another primary acid­base disorder, a simple (uncomplicated) disorder is present. If two or three primary acid­base disorders are simultaneously present, the patient has a mixed (complicated) disorder. If a respiratory acid­base disturbance is present for minutes to hours, it is considered an acute disorder, while if it is present for days or longer it is considered a chronic disorder. Changes that follow the primary disorder and attempt to restore the blood pH to normal are referred to as compensatory changes. Because all metabolic acid­base disorders are chronic and the normal respiratory system can quickly alter the Paco2, essentially all metabolic disorders are accompanied by some degree of respiratory compensation. The amount of compensation (metabolic or respiratory) can be reliably predicted based on the degree of derangement in the primary disorder. Table 28­1 outlines the simple acid­base disorders and provides formulas for calculating the expected compensatory responses. As such, although a patient can simultaneously have acidosis and alkalosis, the end result will be acidemia or alkalemia. Carbon dioxide is a volatile acid regu3 lated by the depth and rate of respiration. Such an alteration may result in the accumulation of Paco2 beyond normal limits (more than 45 mm Hg or 6. Variations in respiratory rate and/or depth allow the lungs to achieve changes in the Paco2 very quickly (within minutes). Bicarbonate is a base regulated by renal metabolism via the - enzyme carbonic anhydrase. Respiratory compensation of metabolic disturbances begins within minutes and is complete within 12 hours. Establishing the specific disease process responsible for the observed acid­base disorder is clinically important because treatment of a given disorder will only be accomplished by correcting the underlying disease process. This means that the positively charged entities reported in a standard chemistry panel (cations: sodium and potassium) should be exactly balanced by the negatively charged entities (anions: chloride and bicarbonate). However, this relationship is consistently incorrect because the measured cations are higher than the measured anions by 10 to 12 mEq/L (10­12 mmol/L). This discrepancy results from the presence of unmeasured anions (eg, circulating proteins, phosphates, and sulfates). Identification of an increased anion gap is very important because a limited number of clinical scenarios lead to this unique acid­base disorder. A mnemonic to recall the differential diagnosis for an anion gap acidosis is shown in Table 28­3. The concept of the increased anion gap is applied later in Patient Encounters 6 through 10. The anion gap may be artificially lowered 3 by decreased serum albumin, multiple myeloma, lithium intoxication, or a profound increase in the serum potassium, calcium, or magnesium. This is a very valuable tool that can be used in narrowing the differential diagnosis of certain acid­base disorders as well as in uncovering occult or mixed acid­base disorders. Once the primary disorder is established, step 2 is to apply the formulas from Table 28­1 to assess whether compensation is appropriate and to look for concurrent processes. Although nomograms are commonly used to identify acid­base disturbances in clinical practice, only individuals who fully comprehend the fundamental concepts of acid­base assessment should use these tools. Also, appreciate that nomograms have limited utility when dealing with complex acid­base derangements. Acid­base disturbances are always manifestations of underlying clinical disorders. Note that Paco2 should be in millimeters of mercury to use the equations in ­ the figure. Tables 28­4 through 28­7 outline the most commonly encountered causes for each of the primary acid­base disorders. The therapeutic approach to each of these acid­base derangements should emphasize a search for the cause, as opposed to immediate attempts to normalize the pH. It is critical to treat the underlying causative process to effectively resolve most observed acid­base disorders. However, supportive treatment of the pH and electrolytes is often needed until the underlying disease state is improved. If the anion gap was initially abnormal, serial chemistries should be followed to ensure that the anion gap resolves with treatment. Case Study 2 the next patient is a 59-year-old man undergoing lung transplant evaluation for advanced emphysema. Case Study 4 this 62-year-old woman with hyperlipidemia has experienced multiple myocardial infarctions resulting in ischemic cardiomyopathy and congestive heart failure. Case Study 5 the final patient in this section is a 46-year-old woman with chronic renal insufficiency who is being hospitalized for Clostridium difficile-associated diarrhea. The etiologies of metabolic acidosis Table 28­3 Mnemonics for the Differential Diagnoses of Metabolic Acidosis Elevated Anion Gapa M-Methanol, metformin U-Uremia D-Diabetic (or alcoholic) ketoacidosis P-Paraldehyde, phenformin I-Isoniazid, iron L-Lactic acidosis E-Ethylene glycol, ethanol S-Salicylates a Normal Anion Gapa U-Ureteral diversion S-Saline infusion E-Exogenous acid D-Diarrhea C-Carbonic anhydrase inhibitors A-Adrenal insufficiency R-Renal tubular acidosis Anion gap = serum sodium concentration ­ (serum chloride concentration + serum bicarbonate concentration). Although there are numerous mnemonics to recall the differential diagnosis of the metabolic acidosis, two simple ones are shown in Table 28­3. High anion gap metabolic acidosis is most frequently caused by lactic acidosis, ketoacidosis, and/or renal failure. Although there is considerable variation, the largest anion gaps are caused by ketoacidosis, lactic acidosis, and methanol or ethylene glycol ingestion. Respiratory compensation requires marked increases in minute ventilation and may lead to dyspnea, respiratory fatigue, and respiratory failure. Acidemia predisposes to ventricular arrhythmias and reduces cardiac contractility, each of which can result in pulmonary edema and/or systemic hypotension. Chronic metabolic acidosis leads to a variety of musculoskeletal problems, including impaired growth, rickets, osteomalacia, or osteopenia. These changes are believed to be caused by the release of calcium and phosphate during bone buffering of excess H+ ions. As previously discussed, in anion gap metabolic acidosis, the isoelectric state is maintained because unmeasured anions are present. With a normal anion gap metabolic acidosis, the isoelectric state is maintained by an increase in the measured chloride. Because of this, normal anion gap metabolic acidosis is often referred to as hyperchloremic acidosis. Additional infusions are given as dictated by the severity and progression of acidosis. Chronic metabolic acidosis can successfully be managed using potassium citrate/citric acid (Polycitra-K, Cytra-K) or sodium citrate/citric acid (Bicitra, Oracit). This occurs because the urinary Cl­ concentration now markedly exceeds the urinary Na+ and K+ concentrations. In order to effectively treat metabolic acidosis, the causative process must be identified and treated. Patients will always hypoventilate to compensate for metabolic alkalosis-even if it results in profound hypoxemia. Rather, complaints are usually related to volume depletion (muscle cramps, positional dizziness, weakness) or to hypokalemia (muscle weakness, polyuria, polydipsia). In order to effectively treat metabolic alkalosis, the causative process must be identified and treated. He has not felt well for the past week and did not attend his regular hemodialysis sessions. When family members found him unresponsive this morning, they sought medical attention. Case Study 8 A 56-year-old woman is brought to the emergency room by rescue squad after several complaints were called in to 911 for a "profoundly intoxicated" individual in a city park. Shortly after arrival in the emergency room she has several episodes of emesis with witnessed aspiration. Case Study 9 A 69-year-old insulin-dependent diabetic man is being evaluated for unresponsiveness. His wife says he had "stomach flu" for several days with frequent bouts of emesis. He became somnolent yesterday and she called an ambulance when she noticed his breathing was very slow and shallow. Case Study 10 the final patient is a 23-year-old woman who was admitted 6 hours ago for diabetic ketoacidosis.

Urispas 200 mg order on line. Face Plus Medispa Muscle Relaxants.

After providing further education and determination of realistic goals muscle relaxer kidney pain urispas 200 mg purchase with amex, providers may then increase the dose of medication xanax muscle relaxant dosage cheap urispas 200 mg line, switch to another therapy infantile spasms 9 months urispas 200 mg buy overnight delivery, or add a therapy if indicated spasms lower back generic urispas 200 mg amex. American Urological Association Guideline on the Management of Erectile Dysfunction: Diagnosis and Treatment Recommendations; updated 2006 spasms below left breast order online urispas. Identify factors that guide selection of a particular -adrenergic antagonist for an individual patient. Formulate a monitoring plan for a patient on a given drug treatment regimen based on patient-specific information. For this reason, clinicians should be knowledgeable about the medical management of this disease. However, in males who have reached 40 years of age, the prostate undergoes a growth spurt, which continues as the male advances in age. The complex enters the nucleus and induces changes in protein synthesis that promote glandular tissue growth of the prostate. Whereas androgens stimulate glandular tissue growth, androgens have no direct effect on stromal tissue. When stimulated, prostatic stroma contracts around the urethra, narrowing the urethra and causing obstructive voiding symptoms. The static factor refers to anatomic obstruction of the bladder neck caused by an enlarged prostate gland. The dynamic factor refers to excessive stimulation of 1A-adrenergic receptors in the smooth muscle of the prostate, urethra, and bladder neck, which results in smooth muscle contraction. The detrusor factor refers to bladder detrusor muscle hypertrophy in response to prolonged bladder outlet obstruction. To further explain, detrusor muscle fibers undergo hypertrophy so that the bladder can generate higher pressure to overcome bladder outlet obstruction and empty urine from the bladder. The hypertrophic detrusor muscle becomes irritable, contracting abnormally in response to small amounts of urine in the bladder. Hence, androgen antagonism does not induce a complete reduction in prostate size to normal. This explains one of the limitations of the clinical effect of 5-reductase inhibitors. An estimated 98% of the -adrenergic receptors in the prostate are found in prostatic stromal tissue. Of the 1-receptors found in the prostate, 70% of them are of the 1Asubtype and the remainder are of the 1B and 1D subtypes. Obstructive symptoms result from failure of the urinary bladder to empty urine when the bladder is full. The patient will complain of a decreased force of the urinary stream, urinary hesitation, dribbling, intermittency, a sensation that the bladder is not empty even after voiding, and straining to empty the bladder. Irritative symptoms, including urinary frequency, nocturia, and urgency, result from the failure of the urinary bladder to store urine until the bladder is full. It is estimated that up to 38% of untreated men with mild symptoms will have symptom improvement over a 2. On the other hand, a significant portion of patients with mild symptoms will likely experience disease progression. Patients with moderate to severe symptoms can experience a decreased quality of life as daily activities are adjusted because of lower urinary tract voiding symptoms. Predictors of disease progression include an enlarged prostate of at least 30 g (1. The patient is instructed to schedule return visits to the clinician every 6 to 12 months. In addition, the patient is educated about implementing nonpharmacologic measures to reduce voiding symptoms (see section on Nonpharmacologic Therapy) and avoiding factors that worsen obstructive and irritative voiding symptoms (Table 52­4). In early stages of disease, the patient may complain of obstructive voiding symptoms. If untreated, the disease may progress and the patient may complain of irritative voiding symptoms or acute urinary retention, which is painful due to maximal distention of the urinary bladder. Also, the patient may be symptomatic of disease complications, including urosepsis, pyelonephritis, cystitis, or overflow urinary incontinence. Symptoms Patients may complain of obstructive voiding symptoms (eg, urinary hesitancy, decreased force of urinary stream, straining to void, incomplete bladder emptying, dribbling, and intermittency) and/or irritative voiding symptoms (eg, urinary frequency, nocturia, and urgency). These tests are not routinely performed but rather are reserved for those patients in whom renal dysfunction is suspected. For each question, the patient can respond using a 1­5 scale, where 0 = not at all or none; 1 = less than 1 time in 5; 2 = less than half of the time; 3 = about half of the time; 4 = more than half of the time; and 5 = almost always Directions for the clinician: After the patient completes the questionnaire, the scores for individual items should be tallied for a final score. Scores of 0­7 = mild symptoms; scores of 8­19 = moderate symptoms; scores more than 20 = severe symptoms Questions to Assess Obstructive Voiding Symptoms 1. How often have you had a sensation of not emptying your bladder completely after you finished urinating How often have you found you stopped and started again several times when you urinated How many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning Refer to the section on Combination Therapy for a detailed description of various regimens and their advantages and disadvantages. For patients who are at risk of disease progression (ie, those with large prostates [greater than 30 g or 1. A transurethral prostatectomy is typically reserved for prostates of intermediate size (30 g [1. To minimize complications of prostatectomy or in patients who are taking anticoagulants, minimally invasive surgical procedures, such as transurethral incision of the prostate, transurethral needle ablation, transurethral microwave thermotherapy or transurethral laser ablation, are options. A decrease in score of 3 points or more is considered a clinically significant improvement. However, minimally invasive surgical procedures are associated with a higher reoperation rate than a prostatectomy. Drug treatment is used in patients with severe disease when the patient refuses surgery or when the patient is not a surgical candidate because of concomitant diseases. During the day, timed voidings every 2 to 3 hours and use of double voiding help to empty urine from the bladder. Patients should avoid excessive caffeine and alcohol intake, because these may cause urinary frequency. Patients should avoid taking nonprescription medications that can worsen obstructive voiding symptoms (eg, antihistamines or decongestants) (see Table 52­4). These drugs competitively antagonize -adrenergic receptors, thereby causing relaxation of the bladder neck, prostatic urethra, and prostate smooth muscle. All -adrenergic antagonists are considered equally effective in relieving symptoms. No has not been studied in patients with specific dosing in patients with creatinine clearance recommendations creatinine clearance < 30 mL/min (0. Contraindicated in be used cautiously undergoes extensive Alfuzosin should Tamsulosin has not patients with severe as it undergoes hepatic metabolism be used cautiously been studied in hepatic impairment extensive hepatic in patients with patients with severe metabolism mild hepatic hepatic impairment impairment Best time to take At bedtime Immediate-release: After meals for best On an empty Take with a meal, which doses anytime during the oral absorption stomach for best decreases extent of day; however, it is oral absorption. Theoretically, typically given at taken 30 minutes this would help decrease bedtime after a meal, as hypotensive adverse Extended-release: recommended by effects anytime during the the manufacturer, day extent of absorption is reduced, thereby further reducing the potential for hypotensive adverse effects Half-life (hours) 12 22 5 10 13 Formulation Immediate-release ImmediateExtended-release Modified-release Immediate-release release and extended-release Cardiovascular ++ ++ + 0 to + 0 to + adverse effects Ejaculation + + + ++ ++ disorders Rhinitis + + + + + Malaise + + + + + +, minimal; ++ moderate. The need for up-titration with a particular -adrenergic antagonist delays its peak onset of action and the time when the patient can experience maximal clinical benefit. Immediate-release formulations of terazosin and doxazosin are quickly absorbed and produce high peak plasma levels. Modified- or extended-release formulations of doxazosin, alfuzosin, and tamsulosin produce lower peak levels, but more sustained therapeutic plasma levels, than immediate-release formulations and have less potential for producing hypotensive episodes. This allows for initiation of treatment with a therapeutic dose, a shorter time to peak onset of clinical effects, and once daily dosing. Hypotensive adverse effects of -adrenergic antagonists can range from asymptomatic blood pressure reductions to dizziness and syncope. This adverse effect occurs in approximately 2% to 14% of treated patients and is most commonly associated with immediate-release terazosin and doxazosin; is less commonly associated with extendedrelease alfuzosin and extended-release doxazosin; and least commonly associated with tamsulosin and silodosin. The first dose should be given at bedtime so that the patient can sleep through the peak serum concentration of the drug when the adverse effect is most likely to occur. A 3- to 7-day interval between each dosage increase should be allowed, and the patient should be maintained on the lowest effective dose of an -adrenergic antagonist. If the patient is noncompliant with his regimen or he skips or interrupts treatment, the -adrenergic antagonist should be restarted using the usual starting dose and then retitrated up. He should not be instructed to simply double up on missed doses or resume treatment with his currently prescribed daily dose, as this can lead to significant hypotension or syncope. Ejaculation disorders, including delayed, absent and retrograde ejaculation, occur with all adrenergic antagonists. This is largely thought to be due to pharmacologic blockade of peripheral -adrenergic receptors at the bladder neck (ie, the bladder neck is unable to close during ejaculation in the presence of -adrenergic blockade), however, a central nervous system mechanism of action cannot be discounted. Ejaculation disorders generally do not necessitate discontinuation of treatment, except in younger patients. Rhinitis and malaise occur with -adrenergic antagonists and are an extension of the pharmacologic blockade of -adrenergic receptors in the vasculature of the nasal mucosa and in the central nervous system, respectively. Tolerance often develops to these adverse effects and they rarely require discontinuation of days to weeks, depending on the need for titration of the dose from a subtherapeutic starting dose to a therapeutic maintenance dose. An adequate clinical trial is considered to be at least 1 to 2 weeks of continuous treatment at a full maintenance dose with any of these agents. Therefore, in patients with significant hepatic dysfunction, these drugs should be used in the lowest possible dose. With the exception of silodosin, these drugs do not require dosage modification in patients with renal dysfunction. The most common dose-limiting adverse effects are hypotension and syncope, which are more common with immediate-release terazosin and doxazosin, less frequent with extended-release doxazosin and alfuzosin, and least frequent with pharmacologically uroselective 1A-adrenergic antagonists-tamsulosin and silodosin. Pharmacologic uroselectivity refers to preferential inhibition of 1A-receptors, which predominate in the prostatic stroma, prostatic urethra, and bladder neck, and 1D-receptors, which predominate in the bladder detrusor muscle. Tamsulosin and silodosin are the only commercially available 1A-adrenergic antagonists with pharmacologic uroselectivity. The only functionally uroselective -adrenergic antagonist is alfuzosin extended-release tablets. Large daily doses of tamsulosin, silodosin, or alfuzosin may cause loss of uroselectivity, with resultant hypotension and dizziness in some patients. Avoid use of topical or oral decongestants, as these may exacerbate obstructive voiding symptoms. Floppy iris or small pupil syndrome has been reported with -adrenergic antagonists, most often with selective 1A adrenergic antagonists. As a result, when the -adrenergic antagonist­treated patient undergoes cataract surgery, the iris can become flaccid, floppy, or billows out. This plus the pupillary constriction interfere with the surgical procedure and increase the risk of intraoperative and postoperative complications. A patient who plans to undergo cataract surgery is advised to inform his ophthalmologist that he is taking an -adrenergic antagonist. Hypotensive adverse effects of terazosin and doxazosin can be additive with those of diuretics, antihypertensives, and phosphodiesterase type 5 inhibitors (eg, sildenafil). In patients at greatest risk for hypotension, or in those patients who tolerate hypotension poorly, including those with poorly controlled coronary artery disease or severe orthostatic hypotension, tamsulosin or silodosin appear to be the safest choice. When initiating sildenafil, tadalafil, or vardenafil, patients who are taking -adrenergic antagonists should be stabilized first on a fixed dose of the -adrenergic antagonist, and then patients should be started on the lowest effective 805 Patient Encounter 2 A 64-year-old man who has essential hypertension and has been taking valsartan 160 mg and hydrochlorothiazide 12. The patient tolerates this regimen well, and his blood pressure is now 140/80 mm Hg. Although the patient has experienced significant improvement in his obstructive voiding symptoms, he also complains of dizziness, lightheadedness, and periodically feels like fainting. They do so by inhibiting 5-reductase, which is responsible for intraprostatic conversion of testosterone to dihydrotestosterone, the active androgen that stimulates prostate tissue growth. When compared with finasteride, dutasteride produces a faster and more complete inhibition of 5-reductase in prostate cells. However, no difference in clinical efficacy or adverse effects has been demonstrated between these two agents. Results showed that patients treated with the combination had greater symptom improvement after 9 months and less disease progression at 4 years than patients treated with single drug therapy. The rationale for the anticholinergic agent is that irritative symptoms (eg, urinary urgency and frequency) are thought to be due to hyperreactive bladder detrusor muscle contraction, which can be ameliorated by blockade of M2 and M3 muscarinic receptors. Thus, the combination may have an additive pharmacologic effect on relieving irritative voiding symptoms. If irritative symptoms do not improve after starting an anticholinergic agent, up-titrating the dose or switching to another anticholinergic agent may be helpful. Patients at the highest risk of anticholinergic agent-induced acute urinary retention include those with a high postvoid residual urine volume (250 mL or more). Finally, the medication profile of patients should be checked for overall anticholinergic burden, which increases the likelihood of anticholinergic adverse effects, including dry mouth, tachycardia, constipation, confusion, and drowsiness. It may be prescribed alone,44 or along with an -adrenergic antagonist45 or 5-reductase inhibitor. This inhibits the proliferation and contraction of prostatic smooth muscle, or enhances the action of nitric oxide. This is a disadvantage in patients with moderate to severe symptoms, as it will take that long to determine whether the drug is or is not effective. Durable responses have been demonstrated in responding patients treated up to 6 years with finasteride and 4 years with dutasteride. Finasteride has been shown to reduce both the incidence of acute urinary retention by 57% and the need for prostate surgery by 55% in patients with significantly enlarged prostate glands (greater than 40 g [1. Adverse effects include decreased libido, erectile dysfunction, and ejaculation disorders, which may persist after the drug is stopped, and gynecomastia and breast tenderness. When used to prevent prostate cancer, these agents reduce the incidence of prostate cancer by 25%, but are suspected to increase the risk of developing moderate to high grade cancer, if prostate cancer does develop.

Amongst the early observation spasms esophagus problems discount 200 mg urispas with mastercard, to support the immunosurveillance theory muscle relaxant injection 200 mg urispas buy with amex, there is increase in the incidence of tumor in transplantaion patients with immunosuppressive drugs spasms heat or ice urispas 200 mg online. But other findings object to this theory of increased incidence of tumors in immunosuppressive therapy spasms thumb joint buy 200 mg urispas overnight delivery. In nude mice (without-thymus) spasms throughout my body purchase urispas 200 mg fast delivery, where there is T cell deficiency; there should be more incidence of cancer, but it does not happen. Further more, although in the individuals with immunosuppressive drug therapy, the incidence of cancer of immune system is more, the incidence of other cancers (breast, colon and lung) is not increased. It has been seen that animals injected with very high doses or low doses of tumor cells develop tumor, but with intermediate doses there is no tumor formation. The mechanism by which a low dose of tumor cells sneaks through is difficult to reconcile the immune surveillance theory. Finally, this theory assumes that there is only qualitative difference in the cancer cells and normal cells. However in virus-induced tumor, there is expression of virus related antigen against which the immune system will react. Nevertheless, apart from the tumors caused by viruses, the basic concept of immune surveillance theory is that the malignant tumor arises only when there is impairment of immune system or when the tumor cell loses its immunogenicity enabling them to escape immunosurveillance, at this time, remains unproved. Inspite of this, it is clear that an immune response can be generated to tumor cells and therapeutic approaches can be aimed at increasing that response to combat malignant cells. This type of immunity does not require antibodies and displays no antibody specificity. Adaptive Immunity When tumor antigens are introduced into experimental animals, it is seen that both, humoral immunity and cell-mediated immunity play important roles in causing destruction of the tumor cells. Complement fixing antibodies bind to tumor cell membrane and promote attachment of complement components ultimately creating pores on tumor cell membrane, resulting in cell disruption. T cell response is most important immune response for the control of growth of antigenic tumor cells. In contrast, the Tc cells have got direct lytic effect on tumor cells, killing tumor cells by disrupting the target membrane and disintegrating the nucleus. Recent studies have shown that some tumor cells have defective antigen processing machinery with the results that class I molecules do not get loaded with peptides and transported to the surface, class I expression is low and even potentially highly immunogenic tumor antigen cannot be presented to the immune system. There are three possibilities, how the activated macrophages bring about destruction of tumor cells. Secondly, the antitumor activity of the activated macrophages are probably mediated by lytic enzymes, reactive oxygen and nitrogen intermediates. Sneaking through (tumor kinetics): Tumor cells administered sufficiently in low doses develop into cancer, while greater doses are rejected. Therefore, tumor cells may sneak through and not be recognized until growth is established. Antigenic modulation: In the presence of antibody, some antigens are modulated of the cell surface. This involves antigen shedding, endocytosis and redistribution within the membrane without a complete loss of determinant from the cell surface. Antigenic modulation facilitates escape by removing target antigens that the immune system effector cells would recognize. Antigen masking: Certain molecules such as sialomucin, which are frequently bound to the surface of the tumor cells, mask tumor antigens and prevent adhesion of attacking lymphocytes. Blocking factors: Soluble tumor antigens compromise the expression of T immunity by saturation of antigen-binding sites, particularly in the tumor environment, where the concentration of the shed antigens likely to be the highest. Antibodies and antigenantibody complex can block the cytotoxicity of the host lymphocytes. The difference in immune response to tumor antigen, shown by different individuals in a species is determined by genetic differences. Tumor products: the subversion of immune response by products of tumors other than antigen can also be envisaged. Similarly, other humoral factors act non-specifically to impair inflammatory response, chemotaxis and the complement cascade or to augment the formation of blood supply within solid tumors. Cytokine Therapy Large-scale production of cytokines has been possible due to cloning the various cytokine genes. A number of experimental and clinical approaches have been made to use recombinant cytokines, to augment the immune response against cancer. One aspect to prevent cancer is to increase the natural defenses by various approaches. Several types of cancer immunotherapies, in current use or underdevelopment are described. These activated lymphocytes mediate the tumor destruction more than the untreated lymphocytes. Tumor contains lymphocytes that have infiltrated the site as a part of immune response. Anti-idiotype monoclonal antibodies have been used with some success in treating human B cell lymphoma and T cell leukemia. A monoclonal antibody to it, raised in mice, but engineered to contain human sequences has been useful in the treatment of B cell lymphoma. A variety of tumors express significantly a number of growth factor receptors, which are promising targets for antitumor monoclonal antibodies. Monoclonal antibodies have also been used to prepare tumor specific antitumor agents. These agents are delivered, specifically to tumor cells without producing delitorious effects on normal cells. Use of immunotoxins, specific for tumor antigens in a variety of cancers (colon, breast, melanoma, lymphoid leukemia) has been evaluated in some trials. Against lymphoma and leukemia, this therapy has exhibited partial or complete remission. Alternatively, antibody enzyme conjugates located at the tumor site could act on systemically administered prodrugs to release toxic drugs, selectively at the critical site. Such vaccines are directed to generate immune response against any malignant cells, remaining in the body. Cancer Vaccines the key element in designing vaccine is the identification of significant tumor antigens by genetic and biochemical approaches. In case of few human cancers, which are of viral origin, vaccination against those viruses may be effective. Steps are also being taken Transplantation Immunology 15 Transplantation refers to transfer of tissues or organs from one site to another. The desire to accomplish transplantation arose from realization that the disease can be cured by implantation of healthy organs or tissue from a donor in place of diseased one in the recipient. Though so many attempts were made earlier, the first successful human kidney transplantation was done between identical twins in 1954. Today transplantation of organs (kidney, pancreas, heart, liver, bone marrow, etc. Before attempting transplanting organ or tissue from a donor to recipient, the blood grouping of both the donor and recipient is essential, as the vascular endothelium of the grafted tissues also ex- presses blood group antigens. Graft rejection the objective of studying transplantation immunology is to prevent graft rejection between genetically non-identical individuals. Various immunosuppressive agents are being used to diminish the immunological reaction of the grafted tissue. But the problem with the long-term use of these agents is detrimental to the recipient of the graft. Autograft Autograft is self-tissue, which can be transferred from one site to the other site in the same individual. Autograft is usually performed in burn patients transferring healthy area to burn area. Isograft Isograft is the tissue transferred between genetically identical individuals (monozygote 214 Textbook of Immunology twins) in human or mice of the same inbred strains. They do not express antigen, foreign to the recipient, hence they do not produce rejection response. In humans, the tissues or organ grafts between two individuals, other than identical twins, fall in this group. Xenograft exhibits the greatest genetic disparity and therefore induces vigorous rejection. Specificity and Memory of the rejected response the time of rejection depends on the tissue involved. Irrespective of these time differences, the immune response involving rejection displays the specificity and memory. The skin becomes revascularized and then there is infiltration of lymphocytes, monocytes, neutrophils and other inflammatory cells. The genetic relationship between the donor and recipient determines whether the rejection will occur. Autografts or isografts are usually accepted, while allografts and xenografts are not. It is seen that nude (thymectomized) survival and the graft was rejected at the same time as that of control mice. When T cell derived from an allograft-primed mouse are transferred to an unprimed syngeneic mouse, the recipient mounts a second-set rejection to an initial allograft from the original allogeneic strain. Such tissues do not evoke immunological response, hence there is no rejection of tissue. Tissues, which display significant antigenic difference, evoke immune response, hence induce rejection. For example, when mice from two different inbred strains, with haplotype b and R are mated, all the F1 progeny inherit one haplotype from each parent (refer. Transplantation in the reverse direction (from F1 to parent) will not succeed because each parent lacks one of the F1 haplotype. While transplantation between members of inbred strain of animals is successful, an exception is seen when the donor is male and the recipient, a female. This unilateral sex-linked histoincompatibility is known as Eichwald-Silmser effect. Major histocompatible complex identity of donor and host is not the sole factor determining tissue acceptance, when the tissue 216 Textbook of Immunology Table 15. The tissue rejection induced by minor histocompatibility difference is usually less vigorous than that induced by major histocompatibility differences. Microcytotoxicity is assessed by the uptake or exclusion of various dyes (trypan blue, eosin) by the cells. Immunologically privileged sites fail to induce an immune response, because they are effectively sequestered (hidden) from the cells of the immune system. These sites include anterior chamber of the eye, cornea, uterus, testis, brain and the cartilages. Each of these sites are characterized by the absence of lymphatic vessels and in some cases, absence of blood vessels. Consequently, the alloantigens of the grafts are not able to sensitize the recipients lymphocytes. Therefore, there is an increase likelihood of acceptance even if the antigens are not matched. Fetus can be considered as an intrauterine allograft as it contains antigens (fetus, which is a part of father), which are foreign to mother. The reason is not clearly known, but however, there are certain explanations in favor of acceptance of the graft. Antigen shedding by fetus blocks the aggressive T cells or antibodies by an enhancement effect. An incomplete mucopolysaccharide barriers, rich in sialic acid, surrounds the trophoblastic cells protecting them from cytotoxic lymphocytes. Mixed Lymphocytic Reaction In this test, the lymphocytes from the potential donor is mixed with the lymphocytes of the recipient. Hence, the donor lymphocytes act as stimulator and the recipient lymphocyte as responder cells. Proliferation of recipient T cells, which indicates T cell activation, is measured by the uptake of 3H-thymidine. Greater the activation of recipient lymphocytes more would be the 3H-thymidine uptake. The rejection may be attributable to the immune reaction against minor histocompatibility antigens. Immunosuppression can be achieved, in animals, by neonatal thymectomy and administration of antilymphocyte serum. Steroids, azathioprine and fungal metabolites (cyclosporin A) are effective agents causing immunosuppression. White blood cells from potential donors and the recipient are added to separate wells of a microtiter plate. The reaction sequence shows that, if the antigen is present on the lymphocytes, addition of complement will cause them to become porous and unable to exclude the added dye; B. Sensitization phase in which there is sensitization and proliferation of reactive lymphocytes. Even if there is tissue incompatibility, there are certain privileged sites (such as the eye and brain), where transplantation does not evoke immune reactions. The increased population of Th cells is thought to play a key role in inducing various effector mechanism of allograft rejection. But the minor histocompatibility antigens are weak and do not produce vigorous rejection. Less common are antibody plus complement-mediated ly- Transplantation Immunology 221. During rejection episode, the level of cytokines increased inducing variety of cells to the graft. Hyperacute Rejection Hyperacute rejection occurs within 24 hours of the graft implantation in patients those who have autoantibodies against the graft.

References

• Hower J, Struck H, Tackman W, Stolecke H. CPK activity in hypoparathyroidism. N Engl J Med. 1972;287:1098.
• Benedetto U, Angeloni E, Refice S, Sinatra R. Radial artery versus saphenous vein graft patency: meta-analysis of randomized controlled trials. J Thorac Cardiovasc Surg 2010;139(1):229-231.
• Aminiahidashti H, Laali A, Nosrati N, Jahani F. Recurrent seizures after lidocaine ingestion. J Adv Pharm Technol Res 6:35, 2015.
• Liu-Smith F, Farhat AM, Arce A, et al. Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure. J Am Acad Dermatol 2017;76(3):499.
• Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of MONOCRYL plus antibacterial suture (Poliglecaprone 25 with triclosan). Surg Infect (Larchmt) 2007;8:201-8.
• Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002; 162: 1477-1481.
• Mayo ME: Lower urinary tract dysfunction in cerebral palsy, J Urol 147(2):419- 420, 1992.